First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Telix-Pharma-TLX591

More Like This

PR Newswire associated0

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC Therapy Candidate in Prostate Cancer

PR Newswire associated0

ProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and Tolerability

PR Newswire associated0

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

PR Newswire associated0

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

PR Newswire associated0

First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

PR Newswire associated0

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

PR Newswire associated0

Illuccix® Approved in the United Kingdom

PR Newswire associated0

Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS